Table 3.

Prognostic importance of SII in testicular cancer patients.

Author (Year)	Reference	Patients (n)	Study Design	Cut-Off Value	Main Findings
Chovanec (2018)	[50]	171	Retrospective translational	1003	SII > 1003 highly correlated with intermediate and poor IGCCCG risk groups, bulky retroperitoneal lymphadenopathy, and elevated tumor markers SII > 1003 was associated with poor OS The combination of low PD-L1 expression and elevated SII correlated with poor prognosis
Fankhauser (2018)	[40]	146	Retrospective cohort	1428	SII > 1428 was significantly associated with poor OS
Imamoglu (2019)	[45]	112	Retrospective cohort	672	SII > 672 was associated with an advanced disease stage
Cursano (2020)	[42]	62	Retrospective cohort	844	SII > 844 highly correlated with worse OS and PFS SII > 844 was associated with poor response to CHT
Yoshinaga (2020)	[47]	63	Retrospective cohort	-	SII was not associated with OS
Bumbasirevic (2022)	[39]	88	Prospective cohort	683.21	Median SII values were significantly lower in Stage I patients compared with Stage II and III patients SII > 683.21 was associated of metastatic disease development SII was associated with 8-hydroxydeoxyguanosine, a representative byproduct of oxidative DNA damage
Kalavska (2022)	[49]	51	Retrospective cohort	1003	SII > 1003 was associated with an increased percentage of neutrophils and decreased percentage of lymphocytes

SII, systemic immune-inflammation index; IGCCCG, International Germ Cell Cancer Collaborative Group; OS, overall survival; PFS, progression-free survival; CHT, chemotherapy; PD-L1, programmed death-ligand 1.